Popular GLP-1 weight-loss drugs linked to lower risks of addiction and overdose

Дата публикации: 03-06-2026 14:04:58

A massive study of more than 600,000 U.S. veterans suggests that popular GLP-1 drugs such as semaglutide may do far more than help with diabetes and weight loss—they could also fight addiction itself. Researchers found that people taking these medications were less likely to develop substance use disorders involving alcohol, nicotine, cannabis, cocaine, opioids, and other drugs, while those already struggling with addiction experienced fewer overdoses, hospitalizations, emergency visits, and drug-related deaths.

Схожие новости

#	Наименование новости	Тональность	Информативность	Дата публикации
1	Oral GLP-1 drugs may quiet the brain’s food craving circuit	0	9.89	25-07-2026
2	Blockbuster weight loss drugs like Ozempic deliver big results but face big questions	0	6.28	11-02-2026
3	Study raises red flags over long-term effectiveness of popular weight loss drugs like Ozempic	0	9.05	28-01-2026
4	Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk	0	9.79	06-06-2026
5	The overlooked nutrition risk of Ozempic and Wegovy	0	8.66	04-02-2026
6	What happens after Ozempic shocked researchers	0	12.57	20-03-2026
7	GLP-1 use hits record high as Medicare opens access to weight-loss drugs	0	7	09-07-2026
8	Most people who stop GLP-1 drugs like Ozempic eventually return	0	8.57	16-06-2026
9	Ozempic and Mounjaro linked to a surprising hair loss risk	0	7.22	24-07-2026
10	Medicare is now covering some GLP-1 weight loss drugs for $50. Here’s what to know	5	7	01-07-2026

Классификация: . Схожих патентов: 0. Схожих новостей: 10. Тональность: 0. Информативность: 9.68. Источник: www.sciencedaily.com.